- Home
- DSP vs ABOS Comparison
DSP vs ABOS Comparison
Compare DSP & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- ABOS
- Stock Information
- Founded
- DSP 1999
- ABOS 1996
- Country
- DSP United States
- ABOS United States
- Employees
- DSP N/A
- ABOS N/A
- Industry
- DSP EDP Services
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- ABOS Health Care
- Exchange
- DSP Nasdaq
- ABOS Nasdaq
- Market Cap
- DSP 291.3M
- ABOS 99.1M
- IPO Year
- DSP 2021
- ABOS 2021
- Fundamental
- Price
- DSP $17.53
- ABOS $1.56
- Analyst Decision
- DSP Strong Buy
- ABOS Strong Buy
- Analyst Count
- DSP 7
- ABOS 3
- Target Price
- DSP $17.71
- ABOS $9.33
- AVG Volume (30 Days)
- DSP 198.1K
- ABOS 379.4K
- Earning Date
- DSP 03-03-2025
- ABOS 11-12-2024
- Dividend Yield
- DSP N/A
- ABOS N/A
- EPS Growth
- DSP N/A
- ABOS N/A
- EPS
- DSP 0.08
- ABOS N/A
- Revenue
- DSP $263,587,000.00
- ABOS N/A
- Revenue This Year
- DSP $28.26
- ABOS N/A
- Revenue Next Year
- DSP $12.19
- ABOS N/A
- P/E Ratio
- DSP $230.51
- ABOS N/A
- Revenue Growth
- DSP 23.73
- ABOS N/A
- 52 Week Low
- DSP $6.50
- ABOS $1.54
- 52 Week High
- DSP $21.74
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- DSP 39.72
- ABOS 30.29
- Support Level
- DSP $16.78
- ABOS $1.69
- Resistance Level
- DSP $19.95
- ABOS $1.88
- Average True Range (ATR)
- DSP 0.88
- ABOS 0.13
- MACD
- DSP -0.40
- ABOS -0.00
- Stochastic Oscillator
- DSP 19.93
- ABOS 4.88
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.